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A phase I and pharmacologic study of Belotecan in combination 
with Cisplatin in patients with previously untreated extensive-stage 
disease small-cell lung cancer
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Joo Hee; Hong, Jeong-Sook; Kang, Yoon-Koo; Lee, Jung-Shin 
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Background: Belotecan (Camtobell®; CKD602) is a novel campto-
thecin derivative antitumor agent. This phase I study was designed to 
determine the maximum-tolerated dose (MTD), toxicity proﬁle, and 
dose-limiting toxicity (DLT) of belotecan in combination with cisplatin 
in patients with previously untreated extensive-stage disease small-cell 
lung cancer (ED SCLC). Furthermore, pharmacokinetics (PK) and pre-
liminary antitumor activity of belotecan against SCLC were evaluated.
Methods: Patients with ED SCLC, age 18-70, ECOG PS 0-2, no prior 
chemotherapy and adequate organ function were eligible. Cisplatin 
with ﬁxed dose of 60 mg/m2 was administered intravenously (i.v.) over 
2 hours on day 1. Belotecan was administered iv as intermittent 30-
minute infusions on days 1 to 4, starting dose of 0.40 mg/m2/day with 
increment of 0.05 mg/m2/day. Modiﬁed Fibonacci escalation was used 
(3 to 6 patients per cohort) and intra-patient dose escalation was not al-
lowed. PK of belotecan was determined during the ﬁrst treatment using 
non-compartmental pharmacokinetic analysis.
Results: Seventeen patients were treated at 4 dose levels (0.40 to 
0.55 mg/m2/day). At 0.55 mg/m2/day of belotecan, the DLT of grade 
4 neutropenia with fever occurred in 2 of 5 patients, and therefore the 
MTD was 0.50 mg/m2/day. Interestingly, out of 17 patients, there were 
14 partial responses (82.4%; 95% CI, 63.4% to 100.0%). PK analysis 
revealed that at 0.50 mg/m2/day, plasma clearance of belotecan was 
5.78 ± 1.32 L/hr and terminal half-life was 8.55 ± 2.12 hr. Fraction of 
excreted amount in urine was 37.36 ± 5.55 %. PK of belotecan were 
not altered by administration of cisplatin, as compared with historical 
control.
Conclusions: The MTD of belotecan was 0.50 mg/m2/day for intermit-
tent 30-min i.v. infusion for 4 days in combination with cisplatin 60 
mg/m2 on day 1 every 3 weeks. Furthermore, very promising antitu-
mor activity against SCLC was observed. The phase II study is being 
conducted now.
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Purpose: Early high-dose chemotherapy was tested in different non-
randomized trials with impressive complete response rate, and over 
the years this approach continued to be proposed without the possibil-
ity to obtain ﬁrm conclusions, but in submitting cohorts of patients to 
signiﬁcant toxicities. The early administration of multiple and sequen-
tial high-dose chemotherapy supported by peripheral blood progenitors 
allowed to increase the dose intensity of chemotherapy by three fold. 
The EBMT carried out a randomized trial to test the impact of such an 
intensiﬁcation on long-term survival of patients with small cell lung 
cancer.
Methods: Patients with limited and extensive disease with ≤2 meta-
static sites were randomized to 6 cycles of standard dose ICE (ifos-
famide 5 g/m2, carboplatin 300 mg/m2, and etoposide 360 mg/m2 over 2 
days every 28 days) or 3 cycles of high-dose ICE (ifosfamide 10 g/m2, 
carboplatin AUC 20, etoposide 1200 mg/m2, all drugs divided over 4 
days, every 28 days) supported by PBPCs previously collected follow-
ing 2 cycles of epidoxorubicin 150 mg/m2 and paclitaxel 175 mg/m2 
and ﬁlgrastim. Due to a low accrual rate an interim analysis was carried 
out with strong boundaries that allowed to close the trial prematurely 
and to obtain ﬁrm and ﬁnal conclusions. 
Results: The median relative dose intensity of the high-dose ICE was 
293% (174% to 392%) compared to the standard ICE. The 3- year 
survival rate was 18% and 19% in the high-dose and standard dose arm 
respectively. The median survival rate were not statistically differ-
ent(18.1 months and 14.4 months), neither the overall (78% and 68%) 
and complete response rate (39% and 34%). An analysis according 
to stratiﬁcation factors (limited vs extensive disease, LDH normal vs 
abnormal, male vs female, PS 0 vs 1) could not disclose any subgroups 
that beneﬁted from the intensive strategy. Hematological toxicity was 
signiﬁcant in the standard arm (grade >3 neutropenia 70%, anemia 
25%, thrombopenia 25%) associated with a toxic death rate at 4%. In 
the high-dose arm, beside the expected severe myelosuppression, the 
toxic death rate was at 10% and the median hospitalization time was 20 
days compared to 4 days for the standard treatment.
Conclusions: Despite an increase in the peak dose, the total dose and 
the dose-intensity by 3 fold ICE chemotherapy did not improve the 
long term outcome of SCLC but was toxic and expensive. This stategy 
should be abandoned.
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(SCLC) with extensive disease (ED)
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Background: Standard treatment for ED achieves a median suvival 
time of 9 months with only 1-2% of long survivors. Biweekly sched-
ules have demostrated to be convenient for patients (pts) with different 
cancers. We assessed the eﬁcacy and toxicity of a biweekly combina-
tion of Cb and G in chemonaïve pts.
Methods: We included pts with ED or limited disease unﬁt for com-
bined radical radiotherapy with ECOG PS 0-2. Pts with brain metasta-
sis were also enrolled. Treatment consisted of: Cb AUC 3 day 1 and G 
2000 mg/m2 day 1 every 14 days, ﬁnal response was assessed after 8 
cycles
